Vivace Therapeutics Gains Orphan Drug Designation for VT3989
Vivace Therapeutics, Inc., a company dedicated to pioneering cancer treatment through small molecule discovery, has exciting news to share. The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to its leading product, VT3989, specifically for the treatment of mesothelioma. This recognition highlights the need for effective therapies in treating this aggressive form of cancer.
Understanding VT3989 and Its Role
VT3989 is an innovative small molecule that acts as a transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor. By targeting the Hippo pathway, it aims to inhibit the palmitoylation of TEAD proteins, which are crucial in cancer development and progression. This unique mechanism positions VT3989 as a potential best-in-class therapeutic option, supported by significant clinical trial data.
Clinical Data and Safety Profile
To date, over 200 patients have participated in an ongoing Phase 1 clinical study evaluating VT3989. The results have been promising, particularly among patients with mesothelioma who did not respond to traditional chemotherapy or immuno-oncology therapies. The safety profile of VT3989 has also been impressive, suggesting its strong potential to meet the urgent needs of patients with limited treatment options.
Future Steps and Commitment to Development
Dr. Sofie Qiao, president and chief executive officer of Vivace Therapeutics, emphasized the significance of this designation. She stated, "The granting of Orphan Drug Designation to VT3989 underscores the critical need for new, effective therapies for mesothelioma, an aggressive cancer with limited treatment options. We are committed to the continued clinical development of VT3989 and plan to discuss moving into a registrational Phase 3 study with the FDA by the end of 2025."
What Is Orphan Drug Designation?
Orphan Drug Designation is granted to encourage the development of treatments for rare diseases that affect fewer than 200,000 patients in the United States. This designation provides various incentives for drug developers, including tax credits for eligible clinical trials, waivers for certain FDA fees, and seven years of market exclusivity post-approval. Such benefits are instrumental in facilitating research and development processes aimed at tackling uncommon yet severe health conditions.
About Vivace Therapeutics
Vivace Therapeutics is committed to addressing high unmet medical needs through its innovative approach targeting the Hippo pathway in cancer therapies. Based in the San Francisco Bay Area, the company has successfully raised $105 million to expedite its development efforts. By focusing on first-in-class approaches, Vivace aims to create effective solutions for human carcinomas, making significant advancements in the field of oncology.
Contact Information
For more information, you may contact:
Dr. Sofie Qiao, Ph.D.
President and CEO
Phone: 650.666.2753
Tim Brons
Vida Strategic Partners (Media)
Phone: 646-319-8981
Frequently Asked Questions
What is VT3989?
VT3989 is an investigational cancer therapy developed by Vivace Therapeutics, targeting the Hippo pathway to treat mesothelioma.
What does Orphan Drug Designation mean?
Orphan Drug Designation is a special status granted by the FDA to encourage development of treatments for rare diseases.
What is the significance of the Phase 1 clinical study?
The Phase 1 study evaluates the safety, tolerability, and efficacy of VT3989, showcasing promising results in mesothelioma patients.
What support does Orphan Drug Designation provide?
This designation offers tax incentives, exemptions from certain fees, and potential market exclusivity to encourage the research of rare conditions.
How can I learn more about Vivace Therapeutics?
You can visit their official website for further information on their research and developments in cancer therapies.
